Shots:

• The P-lll study will assess the efficacy- safety- pharmacokinetics PK/PD- and immunogenicity of SB16 vs Prolia in 432 female volunteers for postmenopausal osteoporosis
• The company has initiated the P-I study to compare the PK/PD- safety- tolerability- and immunogenicity b/w SB16 and Prolia in healthy volunteers in Oct’2020
• Samsung Bioepis has three biosimilar candidates – SB12 (eculizumab)- SB15 (aflibercept)- and SB16 (denosumab) in P-III development

 ­ Ref: Samsung Bioepis | Image: Samsung Bioepis